KR870006086A - 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 - Google Patents

오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 Download PDF

Info

Publication number
KR870006086A
KR870006086A KR860011019A KR860011019A KR870006086A KR 870006086 A KR870006086 A KR 870006086A KR 860011019 A KR860011019 A KR 860011019A KR 860011019 A KR860011019 A KR 860011019A KR 870006086 A KR870006086 A KR 870006086A
Authority
KR
South Korea
Prior art keywords
gpir
modified
producing
reagent
periodate
Prior art date
Application number
KR860011019A
Other languages
English (en)
Other versions
KR950007215B1 (ko
Inventor
까셀라 피에르
부리 베르나르
까나 크자비에
Original Assignee
미셀드아스
소시에떼아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8518981A external-priority patent/FR2591894B1/fr
Priority claimed from FR8611643A external-priority patent/FR2602682B1/fr
Application filed by 미셀드아스, 소시에떼아노님 사노피 filed Critical 미셀드아스
Publication of KR870006086A publication Critical patent/KR870006086A/ko
Application granted granted Critical
Publication of KR950007215B1 publication Critical patent/KR950007215B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음

Description

오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 정맥주사한 천연 리신의 A사슬의 혈장이탈곡선을 나타낸다.
제2도는 정맥주사한 IT AT15E(제1곡선) 및 IT(A-1a)AT15E(제 2곡선)의 시간에 대한 혈장이탈 곡선을 나타낸다.

Claims (11)

  1. GPIR을 과량의 일차아민 존재하에서 퍼요오데이트 이온으로 처리하는 단계를 포함하는, 천연 GPIR의 리보솜-저해 및 GPIR의 생체내 지속작용성을 갖는 변형 GPIR의 제조방법.
  2. 제1항에 있어서, GPIR의 티올기 중 최소한 하나가 퍼요오데이트 이온으로 처리하는 중에 보호됨을 특징으로 하는 변형 GPIR의 제조방법.
  3. 제1항에 있어서, 퍼요오데이트 이온을 빛이 차단된 0~15℃의 pH가 5~7인 수용액내에서 0.2~24시간 처리함을 특징으로 하는 변형 GPIR의 제조방법.
  4. 제1항에 있어서, 반응액이 1~10mg/ml의 반응성 A사슬, 10~50mM 알칼린 퍼요오데이트 및 50~500mM의 일차 아민을 함유함을 특징으로 하는 변형 GPIR의 제조방법.
  5. 제1항에 있어서, 일차 아민이 알킬아민, 아미노산 및 수용성 팹티드 중에서 선택한 지방족 아민 임을 특징으로 하는 변형 GPIR의 제조방법.
  6. 제 5항에 있어서, 아미노산이 글리신, 알라닌, 발린, 루이신, 이소루이신, 아르기닌, 아스파르트산, 글루타민산의 라세믹 또는 인티오머로부터 선택됨을 특징으로 하는 변형 GPIR의 제조방법.
  7. 제 2항에 있어서, 산화 반응전에, SH기를 보호하는 통상적인 시약으로 GPIR을 처리하고, 상기 SH기를 IO4 -이온 및 일차 아민으로 처리한 후에 탈보호함을 특징으로 하는 변형 GPIR의 제조방법.
  8. 제7항에 있어서, SH기를 보호하는 시약이 2,2'-디니트로-5,5'-디티오-디벤조산 및 3-(2-피리딜디술파닐)프로피온산에서 선택되고, SH기를 탈보호가 2-머캡토에탄올의 작용으로 수행됨을 특징으로 하는 변형 GPIR의 제조방법.
  9. 항체 또는 항체단편을 제 1항~제 8항중의 어느 하나에 의한 방법으로 제조한 변형 GPIR과 결합시키는 단계를 포함함을 특징으로 하는, 생체내에서 지속작용을 갖는 면역독소의 제조방법.
  10. 제 9항에 있어서, 항체 또는 항체 단편과 변형 GPIR사이의 결합이 디설파이드 결합으로 이루어짐을 특징으로 하는 면역독소의 제조방법.
  11. 제10항에 있어서, 1-에틸-3-(3-디메틸 아니노프로필)카르보디이미드로 활성화된 3-(2-피리딜디술파닐)프로피온산 또는 N-숙신이미닐-3-(2-피리딜티오)프로피오네이트에서 선택된 서로다른 이작용 ; 시약에 의해 결합이 수행됨을 특징으로 하는 면역독소의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860011019A 1985-12-20 1986-12-20 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 KR950007215B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8518981A FR2591894B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
FR85.18981 1985-12-20
FR8611643A FR2602682B1 (fr) 1986-08-12 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
FR86.11643 1986-08-12

Publications (2)

Publication Number Publication Date
KR870006086A true KR870006086A (ko) 1987-07-09
KR950007215B1 KR950007215B1 (ko) 1995-07-04

Family

ID=26224905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860011019A KR950007215B1 (ko) 1985-12-20 1986-12-20 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법

Country Status (15)

Country Link
US (2) US4911911A (ko)
EP (1) EP0234151B1 (ko)
JP (1) JPH0742316B2 (ko)
KR (1) KR950007215B1 (ko)
AR (1) AR242958A1 (ko)
AU (1) AU602320B2 (ko)
CA (1) CA1276108C (ko)
DE (1) DE3676187D1 (ko)
DK (1) DK611886A (ko)
ES (1) ES2020945B3 (ko)
GR (1) GR3001597T3 (ko)
IE (1) IE59649B1 (ko)
IL (1) IL80972A (ko)
NZ (1) NZ218705A (ko)
PT (1) PT83946B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins
US5234905A (en) * 1991-02-22 1993-08-10 University Of Colorado Foundation, Inc. Soluble CD4 molecules modified to prolong circulating half-life
US5112607A (en) * 1991-06-05 1992-05-12 The United States Of America As Represented By The Secretary Of The Army Potentiation of immunotoxin action by Brefeldin A
SE503711C2 (sv) * 1994-12-14 1996-08-12 Medicarb Ab Flerstegsförfarande för beläggning av en intraokulär lins
US5891506A (en) * 1996-08-09 1999-04-06 Medtronic, Inc. Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
JP2009508938A (ja) * 2005-09-22 2009-03-05 ハダシット メディカル リサーチ サーヴィスィズ アンド ディベロップメント リミテッド 治療上活性な化合物の結合体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
US4154726A (en) * 1978-03-20 1979-05-15 Standard Oil Company (Indiana) Process for modifying the cell wall of single-cell microorganisms using periodate ions
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain

Also Published As

Publication number Publication date
US5104976A (en) 1992-04-14
IL80972A0 (en) 1987-03-31
GR3001597T3 (en) 1992-11-23
US4911911A (en) 1990-03-27
PT83946B (pt) 1989-05-12
AU602320B2 (en) 1990-10-11
AU6663086A (en) 1987-06-25
JPS62167800A (ja) 1987-07-24
IE59649B1 (en) 1994-03-09
PT83946A (fr) 1987-01-01
DE3676187D1 (de) 1991-01-24
JPH0742316B2 (ja) 1995-05-10
KR950007215B1 (ko) 1995-07-04
NZ218705A (en) 1989-10-27
EP0234151B1 (fr) 1990-12-12
IL80972A (en) 1992-08-18
DK611886D0 (da) 1986-12-18
DK611886A (da) 1987-06-21
ES2020945B3 (es) 1991-10-16
IE863305L (en) 1987-06-20
EP0234151A1 (fr) 1987-09-02
CA1276108C (en) 1990-11-13
AR242958A1 (es) 1993-06-30

Similar Documents

Publication Publication Date Title
Cecil et al. The reactions of inter-and intra-chain disulphide bonds in proteins with sulphite
Evans et al. Studies of the binding of different iron donors to human serum transferrin and isolation of iron-binding fragments from the N-and C-terminal regions of the protein
Ishikawa et al. Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining
KR870006086A (ko) 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
FI801035A (fi) Foerfarande foer enzymatisk framstaellning av peptider
Baxter et al. Radiocarbon dating of mortars
ATE229277T1 (de) Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung
SE9100799D0 (sv) Recombinant human factor viii derivatives
DE60042617D1 (de) Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
RU94045908A (ru) Композиция, способ обработки неопластической клетки, способ уничтожения неопластической клетки
ES2095847T3 (es) Desnaturalizacion oxidativa de analitos proteicos.
DK390689D0 (da) Fremgangsmaade til fremstilling af des-b30-insuliner og des-b30-insulinderivater
Tsuji et al. Studies on the Structure of γ-Glutamyltranspeptidase: II. Location of the Segment Anchoring γ-Glutamyltranspeptidase to the Membrane
DK1150999T3 (da) Cyclosporinderivater og fremgangsmåde til fremstilling deraf
Jiang et al. Formaldehyde‐mediated aggregation of protein antigens: Comparison of untreated and formalinized model antigens
DE69915320D1 (de) Immunoglobulin-bindende proteine
ES8102805A1 (es) Procedimiento mejorado para purificar polisacaridos capsula-res
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
Jefferis et al. Studies of human IgD myeloma proteins: Proteolytic digestion patterns
KR900701821A (ko) 카르복실 말단 펩티드 및 단백질을 시컨싱하는 방법
SE7501342L (ko)
KR870006087A (ko) 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
KR970707342A (ko) 화학적으로 보조된 단백질 어닐링 처리 방법(chemically assisted protein annealing treatment)
GB1013577A (en) A process for the modification of proteins
Sperling et al. Simultaneous reduction and mercuration of disulfide bond A6-A11 of insulin by monovalent mercury

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee